By / June 15, 2020

Khiron is growing medical cannabis awareness in Mexico via online classes

In view of the new deadline of the Mexican Court to regulate the medical use of cannabis before the end of 2020 and given the lack of medical training in the field, international specialists will conduct this Monday, June 15th, an online course. The course is aimed at the health and pharmaceutical sector to provide knowledge that will enrich the possibilities of alternative or complementary cannabis-based treatments that could benefit 68 million potential patients in Latin America alone.

The International Director of Medical Services of Khiron, a world leader in medical cannabis, Maria Fernanda Arboleda reported that this course arises from the need to fill the educational gap in medical schools where there is no training in medical cannabis and its benefits.

If you want to know more about cannabis, how Khiron is helping to expand cannabis knowledge and awareness in Latin America, and to find out the latest cannabis news, download the mobile application.

As legalization makes progress, Khiron Life wants to help Mexicans understand the benefits of cannabis

The online course is being held in coordination with the Tec de Monterrey with the aim of adding more doctors who are able to prescribe medical cannabis treatments. That is because currently, in countries where legalization is full, as is the case in Canada, only 10% of doctors say they are comfortable or prepared to prescribe cannabis, unlike patients, where up to 70% arrive for consultations asking about the alternative of medical cannabis.

María Fernanda Arboleda added that the main factor that is stopping the legalization of medical cannabis is precisely the educational limit that is set in the universities, which should take the first step from the training of health professionals to include this topic, which now more than ever is booming because of the multiple benefits it offers to various ailments. However, because of the lack of regulation medical cannabis remains in a dangerous limbo for patients because it is not a panacea that serves all profiles.

There are cases of contraindications that would be counterproductive, such as those related to cardiac arrhythmia, schizophrenia patients, or others, and that is why there is an urgent need to legalize and regulate cannabis. Arboleda hopes that this issue will reach a successful conclusion in December. medical cannabis is already legalized since 2017, but there are no regulations for its operation.

People need to understand the many benefits of cannabis in order to destigmatize the plant

The cannabis plant has more than 100 components, the THC and CBD are the most famous for being the most studied in its use and benefit in the human being. Both can have medical use but it is required a medical accompaniment that guarantees adequate percentages for the personalized treatment of each patient, a matter that is not offered by the illegal market but is currently the only option in Mexico.

In the whole world there are only 30 countries that already allow the medical use of cannabis, and Mexico is halfway through the modification of articles in the General Health Law. However, the country lacks a regulation that allows the elaboration, distribution, and sale of medical supplies derived from cannabis.

“They don’t teach us about what medical cannabis is, what the endocannabinoid system is, what the receptors are, what the THC is, what the CBD is, given much of what is called that stigma and those prejudices that have been attributed to cannabis for so many years. Because of the prohibitionist era in which we have grown up, our knowledge is limited. Currently, we know that more than 70 percent of patients come to the doctor’s office asking or asking the doctor about different cannabis products that can be bought on the Internet,” said María Fernanda Arboleda, international director of Khiron Medical Services.


(Featured image by Startup Stock Photos via Pexels)

DISCLAIMER: This article was written by a third party contributor and does not reflect the opinion of, its management, staff or its associates. Please review our disclaimer for more information.

This article may include forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this article and on this site. Although the Company may believe that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof. Additionally, please make sure to read these important disclosures.

First published in UDGTV, a third-party contributor translated and adapted the article from the original. In case of discrepancy, the original will prevail.

Although we made reasonable efforts to provide accurate translations, some parts may be incorrect. assumes no responsibility for errors, omissions or ambiguities in the translations provided on this website. Any person or entity relying on translated content does so at their own risk. is not responsible for losses caused by such reliance on the accuracy or reliability of translated information. If you wish to report an error or inaccuracy in the translation, we encourage you to contact us.

Comments are closed for this post.